

**Working together** to provide  
unique products that improve patient care





## 2023 Highlights Delivering Our Products to New Patients

### May | Caldolor® Newborn Indication & Study Publication

The FDA approved expanded labeling for our Caldolor product, an intravenously delivered formulation of ibuprofen, to include use in infants. The non-narcotic agent may now be administered for the treatment of pain and fever in patients 3 to 6 months of age. With this newly approved labeling, Caldolor is the only non-opioid product approved to treat pain in infants that is delivered through injection.

We also shared the positive results from a clinical study investigating the safety and pharmacokinetics of Caldolor in newborns, published in the journal *Pediatric Drugs*. The results of the study support the growing body of evidence that demonstrates Caldolor is a safe therapeutic option available to practitioners for the treatment of fever and pain in infants, children and adults.

### June | Expanded Oncology Sales Division

We expanded our oncology sales division as we work to deliver our newest brand Sancuso® – to help cancer patients tolerate their chemotherapy treatments. Sancuso is the first and only FDA-approved prescription patch for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy.

### October | New Vibativ® Pediatric Study Publication

We announced a new publication in *Antimicrobial Agents and Chemotherapy* detailing the results of the first clinical study investigating the safety and pharmacokinetics of our Vibativ product in children 2 to 17 years of age. Vibativ is an intravenous antibiotic approved by the FDA for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections caused by certain gram-positive bacteria. The results of the study suggest that a single dose of Vibativ is safe in children and they experience reduced exposure to Vibativ, compared with the same body weight-based dosing in adults.



## To Our Shareholders, Employees & Partners:

In many ways 2023 was a building year for Cumberland, as we continued to integrate our newest products, while also delivering several significant achievements.

During the year we took a fresh look at our mission statement and refined it to better capture the spirit of what we do each day at Cumberland. Our mission is now: **working together to provide unique products that improve the quality of patient care.**

In designing this statement, we considered several factors.

First, we wanted our mission to address the constituencies we serve, which include patients in need of care, as well as health care providers, our employees, shareholders, partners and community.

We also sought to reflect Cumberland's culture, where teamwork is prized, emphasized and expected – in order to achieve our goals.

Next, it needed to demonstrate our focus on developing, acquiring and distributing differentiated brands.

And finally, we wanted to emphasize that the patient is at the core of everything we do. Our collective efforts are directed at providing unique products that serve as better alternatives for poorly met medical needs.

Now, as we report on the progress we made throughout 2023, we are pleased to share a few exciting updates including the growth opportunities for our portfolio of branded medicines.

Following the FDA's approval to expand the labeling for Caldolor, our non-narcotic agent may now be administered for the treatment of pain and fever in patients 3 to 6 months of age. This expanded use was further supported by the publication of positive results from a clinical study investigating the safety and pharmacokinetics of Caldolor in newborns. We are thrilled to extend Caldolor's labeling for these youngest of patients.

Additionally, we shared the results of the first pediatric study investigating the safety and pharmacokinetics of our Vibativ product. The results suggest that a single dose of Vibativ can be safely administered to children to fight certain serious skin and lung infections.

Meanwhile, we completed the expansion of our oncology sales division as we work to deliver our newest brand, Sancuso, to cancer patients.

As we remain focused on delivering our products to patients within the U.S., we continue to work with our partners in their efforts to register and launch Vibativ in several international markets, which should provide significant future catalysts for the brand.

We also continue to progress our pipeline of innovative products designed to improve patient care and patients' quality of life. Our ifetroban product candidate is being evaluated in a number of Phase II clinical trials for patients with a series of unmet medical needs.

It has now been dosed in nearly 1,400 subjects and has been found to be safe and well tolerated in those individuals. We look forward to sharing the results from these studies as they emerge and then deciding on the best development path for the product, which we believe has the potential to benefit many patients.

We remain committed to fulfilling our newly refined mission by building a portfolio of specialty pharmaceutical brands, which we do by maximizing the potential of our commercial brands, progressing our pipeline and also pursuing select acquisitions.

All the best,

A.J. Kazimi  
Chairman and Chief Executive Officer

## Products to enhance patients' lives



For more information on Cumberland's approved products, including safety and full prescribing information, please visit links to the individual product websites, which can be found on our corporate website, [www.cumberlandpharma.com](http://www.cumberlandpharma.com).

### Addressing unmet medical needs through our product portfolio

With a focus on underserved, specialty markets, including hospital acute care, gastroenterology and oncology, we develop and acquire medicines that are designed to offer distinct advantages over prior treatments.

Our portfolio of FDA-approved brands is supported through our hospital, field, and oncology sales divisions along with our national accounts and field-based medical teams across the United States.

Our commercial product line includes the brands shown below.



### IV **ACETADOTE**

**(acetylcysteine)** An injection used for the treatment of acetaminophen poisoning, which is the leading cause of drug toxicity in the U.S.

### Sancuso®

**(granisetron)** The first and only FDA-approved prescription patch that prevents nausea and vomiting in patients receiving certain types of chemotherapy treatment

### **Vaprisol**

**(conivaptan)** The first and only intravenously administered vasopressin receptor antagonist, which is used to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia

### **KRISTALOSE**

**(lactulose)** The only branded prescription laxative product that combines the established safety and efficacy of lactulose with the convenience and portability of a pre-measured dose

### **CALDOLOR**

**(ibuprofen)** The first injectable therapy approved in the U.S. for the treatment of both pain and fever

### **VIBATIV**

**(telavancin)** An injection used for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections

# Building a Pipeline of Differentiated Products

In addition to our portfolio of FDA-approved brands, we continue to advance our pipeline of new product candidates. All part of our ifetroban program, our development candidates have the potential to help multiple patient populations and are designed to treat conditions for which there is currently no FDA-approved pharmaceutical treatment.

## Our Pipeline Includes:

Preclinical	IND	Phase I	Phase II	Phase III	NDA
			<p><b>Dyscorban®</b> An oral capsule to treat cardiomyopathy associated with duchenne muscular dystrophy (DMD), a fatal, genetic neuromuscular disease</p> <p>The FDA has cleared the Investigational New Drug (IND) application for this program and a Phase II clinical trial in DMD patients has been initiated, with enrollment advancing.</p> <p>The FDA has also provided grant awards of over \$1 million to support this study.</p>		
			<p><b>Vascular®</b> An oral capsule to treat systemic sclerosis (SSc), also known as scleroderma, a rare, debilitating autoimmune disorder that results in a thickening of the skin and internal organs</p> <p>With FDA clearance of our IND, this Phase II study in SSc patients is well underway.</p>		
			<p><i>We are also developing an oral capsule to treat idiopathic pulmonary fibrosis (IPF), the most common form of progressive fibrosing interstitial lung disease</i></p> <p>Following FDA clearance of our IND, we are in the process of initiating our Phase II study in IPF patients in centers of excellence across the U.S.</p>		



## Cumberland Emerging Technologies

A collaboration to advance biomedical innovation

The U.S. leads the world in biomedical innovation, including the development of new medicines. To create a long-term product pipeline and also help build the local biomedical industry, we formed Cumberland Emerging Technologies (CET). As a majority owned subsidiary of Cumberland Pharma, CET helps inventor scientists and life science companies develop health care solutions and provides needed support to advance these solutions toward the commercial marketplace.

CET represents a joint initiative between Cumberland Pharmaceuticals, Vanderbilt University, Launch Tennessee – a state-supported network created to empower Tennessee’s entrepreneurial ecosystem – and WinHealth Pharmaceuticals – our international partner.

At CET we team with academic research groups and support the development process for selected projects, providing critical expertise on intellectual property, regulatory, manufacturing and marketing issues essential to the successful development of new biomedical products.

CET partners with several major academic research institutions, led by joint activities with Vanderbilt University and the Vanderbilt Medical Center. Together we work to identify early-stage biomedical research opportunities and develop the resulting new biopharmaceutical product candidates to improve patient care.

CET has also established and manages the Nashville Life Sciences Center, which serves as an incubator for Middle Tennessee’s emerging biomedical industry.

The Life Sciences Center provides offices, laboratory space, and equipment to early-stage companies looking to develop their technologies and products. We maintain the Cumberland Pharmaceuticals formulation and testing laboratory at the CET Life Sciences Center.

Nearly 30 life science companies exist today because of CET, including a vibrant group of current tenants at the Life Sciences Center as well as a growing number of successful graduates.



# Providing Medicines to Patients Around the World

## A look at our key international partnerships

To provide for the availability of our products, we have established a network of distribution partners. Our international partners are responsible for registering and commercializing select Cumberland products, allowing us to provide our unique medicines to better the quality of patient lives in their countries.

Bringing our medicines to patients throughout the world through a growing network of distinguished international partners



### Tennessee

**Cardinal Health Inc.** provides warehousing, shipping and other distribution support for our products in the U.S.

### Mexico

**PiSA Pharmaceutical** is our commercial partner for Caldolor.

### Saudi Arabia and Jordan

**Tabuk Pharmaceutical Manufacturing Company** is our commercial partner for Vibativ.

### Australia

**Phebra Pty Ltd.** is our commercial partner for Acetadote and Caldolor.

### India

**Sandor Medicoids Pvt. Ltd.** is our commercial partner for Caldolor.

### Russia and CIS

**R-Pharm JSC** is our commercial partner for Vibativ.

### South Korea

**D.B. Pharm Korea Co. Ltd.** is our commercial partner for Caldolor and Vibativ.

### China

**WinHealth Pharma Group** is our commercial partner for Caldolor and Acetadote, and an investor in Cumberland Emerging Technologies.

**SciClone Pharmaceuticals** is our commercial partner for Vibativ.

# VIBATIV

## WHEN YOUR NEXT STEP IS CRITICAL

The once-daily antibiotic infusion with a dual mechanism of action indicated for MRSA and MSSA

## Sustainability 2023 At a Glance

### ENVIRONMENT



#### Supplies

Contracted with third-party companies for the manufacturing, packaging and warehousing of our products

#### Waste

Ensured strict guidelines and processes for the safe, permanent disposal of all unused product

#### Returns

Received and disposed of **5,891** pounds of damaged and expired products

### SOCIAL Community Involvement



**Cumberland Pharma Foundation**  
Contributed to Denver Health, Loyola University, Tennessee State Museum, American Heart Association, Tennessee Historical Society, Belmont University & University of Mississippi

#### Sponsorships

Nashville Health Care Council's Wall Street's View of Healthcare Event

#### Associations

- Nashville Health Care Council
- Life Science Tennessee
- Nashville Chamber of Commerce

#### Life Sciences Center

Provide a lab and incubator to help build the biomedical industry in our area

### GOVERNANCE Board



Independent – 7 of 8

Tenure – Average 9.8 years

Age – Average 66 years

Male/ Female – 6/1

Turnover – None

Board Meeting Attendance  
**100%**

Standing Committee Attendance  
**100%**

### GOVERNANCE Government Relations

**Cumberland Health & Wellness PAC**  
Supports candidates, elected officials and relevant legislation

### GOVERNANCE Compliance



**Code of Conduct**  
Establishes guidelines for all Board members and employees

**Ethical Marketing**  
No government judgments, decrees or fines

**Health Care Professionals**  
All reports regarding relations filed on time

### SOCIAL Employees



Male – 56%  
Female – 44%

Minorities – 15%

Ages  
6.5% below 30  
27.5% between 30 & 50  
66% over 50

Tenures  
35% @ 5 or more years  
25% @ 10 or more years  
10% @ 15 or more years

Turnover – 19.1%

Additions – 20%

**Career Development Program**  
Available to all corporate employees

**Cumberland Academy**  
Provides industry training for corporate employees

**Training**  
Average \$4,000 per full-time employee

**Work-related injuries**  
None

### SOCIAL Patients



Provided **3 million doses** of our products to patients

#### Drug Safety Results

- No products listed in the FDA's MedWatch Safety Alerts
- No products recalled

**Patient AffordAbility**  
We cover up to **71%** of patient Rx costs through coupons for our GI brand

**Clinical Trials Safety**  
No trials terminated due to failure to practice good clinical standards

**Advocacy Groups Supported**

- Muscular Dystrophy Association
- Parent Project Muscular Dystrophy

## Selected Financial Data

Our strategy involves maximizing the potential of our existing brands while continuing to build a portfolio of unique, differentiated products. The result of these efforts has strengthened our market presence, diversified our revenue stream and delivered positive cash flow from operations in 2023.

(dollars in thousands except per share data)	2019	2020	2021	2022	2023
Net Revenues	\$47,553	\$37,441	\$35,985	\$42,011	\$39,553
Less Total Expenses	51,091	40,780	39,493	47,661	45,884
Net Income (Loss)	(3,538)	(3,339)	(3,508)	(5,650)	(6,331)
Cash Flow from Operating Activities	3,056	5,415	6,342	8,453	6,094
Total Assets	104,549	96,463	84,460	92,925	81,776
Total Liabilities	53,464	49,590	41,858	56,951	52,516
Total Equity	51,085	46,873	42,602	35,974	29,260

### Reconciliation of Net Income (Loss) Attributable to Common Shareholders to Adjusted Earnings and Adjusted Diluted Earnings Per Share <sup>(1)</sup> (Unaudited)

(dollars in thousands except per share data)	2019	2020	2021	2022	2023
Net Income (Loss) from Continuing Operations	(\$3,538)	(\$6,625)	(\$5,597)	(\$5,650)	(\$6,331)
Adjustments to Net Income (Loss)					
Income Tax Expense (Benefit)	(79)	56	35	69	46
Depreciation and Amortization	4,404	4,749	4,606	5,328	8,280
Share-Based Compensation	1,486	1,047	742	447	365
Other Adjustments to Net Income <sup>(1)</sup>	-	440	(1,051)	1,368	(347)
Interest Income	(243)	(75)	(26)	(98)	(287)
Interest Expense	246	263	98	586	668
Adjusted Earnings	(\$2,276)	(\$146)	(\$1,193)	\$2,050	\$2,394
Adjusted Diluted Earnings per Share	(\$0.32)	(\$0.01)	(\$0.08)	\$0.14	\$0.17
Diluted Weighted-Average Common Shares Outstanding:	15,764	15,162	14,905	14,809	14,526

(1) The supplemental financial measures are Non-GAAP as defined, the reconciliation of these supplemental measures is above.



## Board of Directors



**A.J. Kazimi**  
Chairman  
Chief Executive Officer  
Cumberland Pharmaceuticals



**James R. Jones**  
Director  
Former Managing Partner  
KPMG LLP-Nashville



**Dr. Gordon R. Bernard**  
Director  
Professor of Medicine  
Division of Pulmonary & Critical Care Medicine  
Vanderbilt University Medical Center



**Kenneth J. Krogulski**  
Lead Director  
Managing Partner and  
Chief Investment Officer  
Berkshire Asset Management



**Martin S. Brown**  
Director  
Attorney of Counsel  
Adams and Reese LLP  
Former Board Director  
Brown-Forman Corporation



**Caroline R. Young**  
Director  
Vice President of Partnership Development  
Frist Cressey Ventures  
Former President  
Nashville Health Care Council



**Joseph C. Galante**  
Director  
Former Chairman  
Sony Music Nashville  
Former President  
RCA Records

## Corporate Information

### Stock Listing

NASDAQ Global Select  
Market Ticker Symbol: CPIX

### Annual Meeting

9:30 a.m. Central Time  
Wednesday, April 24, 2024  
Cumberland Headquarters  
1600 West End Avenue, Suite 1300  
Nashville, TN 37203

### Independent Registered Public Accounting Firm

Carr, Riggs & Ingram, LLC  
3011 Armory Drive, Suite 300  
Nashville, TN 37204  
(615) 665-1811

### Transfer Agent and Registrar

Continental Stock Transfer  
& Trust Company  
1 State Street, 30th Floor  
New York, NY 10004  
(800) 509-5586  
(212) 509-4000  
cstmail@continentalstock.com

### Forward-Looking Statements

This annual report includes forward-looking statements regarding expected future results of the company. A variety of factors could cause actual results to differ materially from expected results. Please see the risk factors more fully described in our Annual Report on Form 10-K for the year ended December 31, 2023, which is filed with the U.S. Securities and Exchange Commission.

### Company Headquarters

Cumberland Pharmaceuticals Inc.  
1600 West End Avenue, Suite 1300  
Nashville, TN 37203  
Phone: (615) 255-0068  
Toll Free: (877) 484-2700  
Fax: (615) 255-0094



